Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Bergen
Helse-Bergen HF
Norwegian Cancer Society
Information provided by (Responsible Party):
Helga B Salvesen, University of Bergen Identifier:
First received: December 26, 2007
Last updated: December 22, 2014
Last verified: December 2014
The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Condition Intervention
Endometrial Neoplasms
Neoplasm Metastasis
Procedure: Tumor biopsy study

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.

Resource links provided by NLM:

Further study details as provided by University of Bergen:

Primary Outcome Measures:
  • Presence of lymph node metastases [ Time Frame: At primary treatment ]

Secondary Outcome Measures:
  • Recurrent disease, death from disease [ Time Frame: 5 years after primary treatment ]

Biospecimen Retention:   Samples With DNA
Tumor specimens from endometrial carcinoma, from curettage and hysterectomy specimens, formalin-fixed and paraffin-embedded and fresh frozen, stored at minus 80 °C, corresponding blood samples with normal DNA

Estimated Enrollment: 1000
Study Start Date: April 2001
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Consecutive numbers
Patients with endometrial cancer
Procedure: Tumor biopsy study
Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.

Detailed Description:
This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women with endometrial carcinoma that undergo an endometrial biopsy before treatment with hysterectomy with bilateral salpingoophorectomy with or without pelvic lymph node staging.

Inclusion Criteria:

  • Women with endometrial carcinoma
  • Available endometrial biopsy
  • Informed consent

Exclusion Criteria:

  • No informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00598845

Contact: Britt Edvardsen, AVD ING +4755974200 ext 6336
Contact: Ingjerd Bergo, Tech +4755974200

Gynecological Oncology, UZ Gasthuisberg Recruiting
Leuven, Belgium, 3000
Contact: Frederic Amant, MD, PhD   
Sentralsykehuset i Førde Recruiting
Førde, Norway, N6807
Contact: Tjugum Jostein, MD, PhD    +4757 83 90 00   
Helse-Fonna, Haugesund Sjukehus Recruiting
Haugesund, Norway, N5528
Contact: Klaus Oddenes, MD   
Kvinneklinikken, Akershus Universitetssykehus Recruiting
Lørenskog, Norway, N1478
Contact: Marie E Engh, Prof   
Kvinnesenteret, Ullevål Universitetssykehus Recruiting
Oslo, Norway, N0450
Contact: Annetine Staff, MD PhD   
Department of Gynecology, St Olav's Hospital Recruiting
Trondheim, Norway, N7006
Contact: Solveig Tingulstad, Prof    +4772574957   
Sykehuset Vestfold HF Recruiting
Tønsberg, Norway, N3103
Contact: Jan A. Rokne, MD   
Department of Gynecology, Ålesund Hospital Recruiting
Ålesund, Norway
Contact: Margareth S. Lode, MD         
Senter for Surgical Gynecologic Oncology, Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden, SE-41345
Contact: Janusz Marcickiewicz, MD, PhD   
Sponsors and Collaborators
University of Bergen
Helse-Bergen HF
Norwegian Cancer Society
Principal Investigator: Helga B. Salvesen, Prof., MD, PhD University of Bergen
  More Information

Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Helga B Salvesen, Professor, MD, PhD, University of Bergen Identifier: NCT00598845     History of Changes
Other Study ID Numbers: NSD 15501
REK 96/1478-2
Helse Vest 911351
Study First Received: December 26, 2007
Last Updated: December 22, 2014

Keywords provided by University of Bergen:
Endometrial cancer
Molecular markers
Lymph node metastasis
Prospective study
Cancer of Endometrium
Tumor Markers, Biological

Additional relevant MeSH terms:
Endometrial Neoplasms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female processed this record on April 28, 2017